Causaly announced new scientific AI agents that provide research teams with the industry's most comprehensive biomedical knowledge for drug discovery. With agentic AI in Causaly Discover, life sciences teams can access, analyze, and synthesize information across the Causaly Knowledge Graph and internal and external data sources. Now researchers can tap into...
Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline.
Isomorphic Labs, an AI-first drug design and development company, announced it has raised $600 Million in its first external funding round. The financing...
AZmed, one of the leading AI companies in medical imaging, announced that it has received two new U.S. Food and Drug Administration (FDA) clearances for its AI tool AZchest. The clearances include applications intended to assist radiologists in the interpretation and detection of chest X-rays for lung nodules and...
Techcyte, a leader in AI-powered digital pathology, announced the launch of Fusion, the first open, standards-based, SaaS platform designed to unify anatomic and clinical pathology workflows. By bringing together pathology teams, IT systems, and AI into a single, integrated platform, Fusion aims to eliminate workflow silos, enhance diagnostic accuracy,...
AIRA Matrix, a leading innovator in AI-driven QC solutions, and Gestalt, an industry leader in IMS and digital pathology, have formed a strategic partnership to bring AIRA Matrix's advanced AI solution, AIRAQC, to Gestalt's PathFlow. This collaboration marks a significant step toward enhancing diagnostic precision and efficiency in laboratories...
Leveraging NVIDIA's Latest GPU Architecture to Accelerate Innovations in Ultra-Low-Dose Imaging and Enhanced Lesion Visualization
Medical imaging faces several critical challenges. Imaging modalities like MRI, PET, and CT are used in over five hundred million patients annually for diagnosis and treatment, involving long scan times and/or potentially high radiation and...
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group, one of Asia's largest independent asset management firms, with strong participation from industry- and technology-focused new investors,...
Caliber has launched four digital solutions that strengthen its portfolio and position the company at the forefront of the Pharma 4.0 revolution. These innovations integrate AI and next-generation technologies to reinforce Caliber's commitment to future-proofing the life sciences industry through holistic digital enablement and optimized compliance.
With over 23 years of...
Flagship Pioneering, the bioplatform innovation company, unveiled Lila Sciences, a company building the world's first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences. The company, which was founded in Flagship's labs in 2023, is pioneering an advanced form of AI that can not only...
Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced to unveil its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM. This new platform, powered by advanced artificial intelligence, integrates seamlessly with the company's proprietary Harbour Mice® technology platform, aiming to accelerate antibody discovery across...
